Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
RAPT

RAPT - RAPT Therapeutics Inc Stock Price, Fair Value and News

3.48USD-0.07 (-1.97%)Market Closed

Market Summary

RAPT
USD3.48-0.07
Market Closed
-1.97%

RAPT Stock Price

View Fullscreen

RAPT RSI Chart

RAPT Valuation

Market Cap

121.5M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

106.29

EV/EBITDA

-1.72

Price/Free Cashflow

-1.15

RAPT Price/Sales (Trailing)

RAPT Profitability

EBT Margin

-4532.02%

Return on Equity

-90.23%

Return on Assets

-75.76%

Free Cashflow Yield

-87.23%

RAPT Fundamentals

RAPT Revenue

Revenue (TTM)

1.5M

RAPT Earnings

Earnings (TTM)

-118.0M

Earnings Growth (Yr)

-4.27%

Earnings Growth (Qtr)

1.15%

Breaking Down RAPT Revenue

Last 7 days

-13.6%

Last 30 days

-13%

Last 90 days

-58.9%

Trailing 12 Months

-83.5%

How does RAPT drawdown profile look like?

RAPT Financial Health

Current Ratio

7.01

RAPT Investor Care

Shares Dilution (1Y)

1.63%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20223.2M3.2M2.3M1.5M
20215.3M4.9M4.4M3.8M
20200005.0M

Tracking the Latest Insider Buys and Sells of RAPT Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 05, 2024
brockstedt dirk g.
sold
-20,456
22.78
-898
chief scientific officer
Dec 29, 2023
brockstedt dirk g.
acquired
49,440
6.18
8,000
chief scientific officer
Dec 21, 2023
ho william
sold
-54,200
21.68
-2,500
chief medical officer
Nov 28, 2023
ho william
sold
-20,580
13.72
-1,500
chief medical officer
Oct 03, 2023
ho william
sold
-39,425
15.77
-2,500
chief medical officer
Aug 18, 2023
ho william
sold
-47,300
18.92
-2,500
chief medical officer
Jul 28, 2023
ho william
acquired
5,520
12.00
460
chief medical officer
Jun 23, 2023
ho william
acquired
11,040
12.00
920
chief medical officer
Apr 19, 2023
ho william
sold
-94,400
18.88
-5,000
chief medical officer
Apr 13, 2023
ho william
acquired
5,520
12.00
460
chief medical officer

1–10 of 50

Which funds bought or sold RAPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
65.84
-39,714
59,286
0.01%
May 17, 2024
Ikarian Capital, LLC
new
-
1,388,530
1,388,530
0.15%
May 16, 2024
COMERICA BANK
reduced
-0.45
-3,548
1,993
-%
May 16, 2024
JANE STREET GROUP, LLC
added
58.13
-813,374
1,084,470
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-6.84
-408,001
207,061
-%
May 15, 2024
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)
added
18.1
-881,612
656,330
0.05%
May 15, 2024
QUADRANT CAPITAL GROUP LLC
new
-
1,114
1,114
-%
May 15, 2024
ORBIMED ADVISORS LLC
sold off
-100
-6,993,110
-
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
sold off
-100
-2,749,330
-
-%
May 15, 2024
Voya Investment Management LLC
reduced
-3.1
-1,030,460
555,269
-%

1–10 of 39

Are Funds Buying or Selling RAPT?

Are funds buying RAPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RAPT
No. of Funds

Unveiling RAPT Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
deep track capital, lp
5.22%
1,793,966
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
9.9%
3,413,552
SC 13G/A
Feb 14, 2024
redmile group, llc
9.9%
3,776,847
SC 13G/A
Feb 14, 2024
perceptive advisors llc
6.2%
2,139,950
SC 13G/A
Feb 13, 2024
vanguard group inc
5.98%
2,056,221
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
7.1%
2,453,049
SC 13G/A
Jan 23, 2024
state street corp
4.23%
1,454,556
SC 13G/A
Oct 23, 2023
deep track capital, lp
5.80%
1,991,403
SC 13G
Jun 12, 2023
price t rowe associates inc /md/
10.4%
3,556,462
SC 13G/A

Recent SEC filings of RAPT Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
8-K
Current Report
May 09, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Apr 05, 2024
ARS
ARS

Peers (Alternatives to RAPT Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

RAPT Therapeutics Inc News

Latest updates
MarketBeat10 hours ago
GlobeNewswire09 May 202407:00 am
Marketscreener.com09 May 202407:00 am

RAPT Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Revenue---886,000641,000756,000966,000869,0001,222,0001,302,0001,528,0001,277,000935,000
Operating Expenses12.7%24,431,00021,678,00019,795,00021,418,00018,790,00019,499,00016,950,00017,783,00014,387,00016,109,00013,788,00013,972,000
  S&GA Expenses-2.0%4,977,0005,079,0005,436,0004,748,0004,491,0003,774,0003,760,0004,012,0003,483,0003,197,0002,802,0003,289,000
  R&D Expenses17.2%19,454,00016,599,00014,359,00016,670,00014,299,00015,725,00013,190,00013,771,00010,904,00012,912,00010,986,00010,683,000
EBITDA Margin-49.5%-44.63-29.85-21.01-21.12-17.90-14.43-11.88-----
Income Taxes---------199,000287,000267,000237,000
Earnings Before Taxes------17,929,000-18,651,000-16,110,000-16,514,000-12,536,000-14,344,000-12,120,000-12,902,000
EBT Margin-49.5%-45.32-30.31-21.30-21.41-18.15-14.64-12.09-----
Net Income-8.1%-22,951,000-21,235,000-19,184,000-20,468,000-17,929,000-18,651,000-16,110,000-16,514,000-12,735,000-14,631,000-12,387,000-13,139,000
Net Income Margin-59.0%-54.90-34.52-23.46-22.64-18.15-14.68-12.19-----
Free Cashflow-32.9%-22,898,000-17,230,000-15,761,000-15,727,000-21,075,000-12,589,000-13,980,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-10.1%15617320022124826620922218819921723110611912914015185.0058.0062.0066.00
  Current Assets-8.3%14816218720723525319821017619321422810311612613614781.0051.00--
    Cash Equivalents-4.6%45.0047.0054.0050.0046.0039.0028.0057.0032.0024.0060.0086.0025.0025.0020.0029.0092.0077.0048.00--
  Net PPE-8.5%2.002.003.003.003.003.003.003.003.003.003.003.003.003.003.003.004.004.004.00--
Liabilities-5.0%25.0026.0027.0021.0028.0021.0020.0020.0020.0012.0016.0014.0014.0015.00---11.00---
  Current Liabilities-3.1%21.0022.0022.0015.0022.0014.0014.0013.0012.0010.0013.0010.0011.0012.0016.0013.0013.009.005.00--
Shareholder's Equity-11.0%13114717320022024518920216818620221892.0010411012313273.00---
  Retained Earnings-6.3%-515-484-453-422-397-367-344-323-304-284-266-247-231-214-202-187-175-161-148--
  Additional Paid-In Capital2.3%64663262762261761353552747347146846532331931231030723524.00--
Shares Outstanding12.3%39.0034.0038.0038.0038.0034.0034.0030.0030.0030.0029.0025.00---------
Float----399---319---622---437-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations2.2%-27,084-27,706-21,884-28,808-18,602-22,849-17,149-15,195-15,578-20,681-12,519-13,916-13,910-15,366-9,953-6,427-8,745-5,688-12,139-9,013-8,634
  Share Based Compensation21.9%5,3984,4294,3294,2394,0943,0252,8652,6722,7022,0862,2912,8882,6872,5582,0052,0352,088896431347377
Cashflow From Investing-23.0%15,88720,63925,74932,43725,308-41,270-17,599-10,45823,837-15,892-14,174-63,69212,41115,4951,060-57,009-46,98120.00-76.00-368-419
Cashflow From Financing1872.9%9,03645810676711675,3595,25150,438132601472139,1081,3014,56016586469,87234,7416637,4857,013
  Buy Backs--------------------65.00109
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

RAPT Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 24,781$ 25,574
General and administrative7,7375,988
Total operating expenses32,51831,562
Loss from operations(32,518)(31,562)
Other income, net1,9972,291
Net loss(30,521)(29,271)
Other comprehensive income (loss):  
Unrealized gain (loss) on marketable securities(113)365
Total comprehensive loss$ (30,634)$ (28,906)
Net loss per share, basic$ (0.79)$ (0.76)
Net loss per share, diluted$ (0.79)$ (0.76)
Weighted average number of shares used in computing net loss per share, basic38,625,36538,280,539
Weighted average number of shares used in computing net loss per share, diluted38,625,36538,280,539

RAPT Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 45,317$ 47,478
Marketable securities96,262111,384
Prepaid expenses and other current assets6,7812,920
Total current assets148,360161,782
Property and equipment, net2,2392,448
Operating lease right-of-use assets4,7725,228
Other assets4473,871
Total assets155,818173,329
Current liabilities:  
Accounts payable6,7715,176
Accrued expenses11,80714,103
Operating lease liabilities, current2,5082,448
Other current liabilities82109
Total current liabilities21,16821,836
Operating lease liabilities, non-current3,8154,458
Total liabilities24,98326,294
Commitments and contingencies
Stockholders' equity:  
Preferred stock
Common stock33
Additional paid-in capital646,045631,611
Accumulated other comprehensive gain (loss)(10)103
Accumulated deficit(515,203)(484,682)
Total stockholders' equity130,835147,035
Total liabilities and stockholders' equity$ 155,818$ 173,329
RAPT
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITErapt.com
 INDUSTRYBiotechnology
 EMPLOYEES122

RAPT Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for RAPT Therapeutics Inc? What does RAPT stand for in stocks?

RAPT is the stock ticker symbol of RAPT Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RAPT Therapeutics Inc (RAPT)?

As of Thu Jun 13 2024, market cap of RAPT Therapeutics Inc is 121.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers.

What is the fair value of RAPT stock?

You can check RAPT's fair value in chart for subscribers. The fair value of RAPT Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RAPT Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RAPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RAPT Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RAPT is over valued or under valued. Whether RAPT Therapeutics Inc is cheap or expensive depends on the assumptions which impact RAPT Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RAPT.

What is RAPT Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, RAPT's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 106.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RAPT PE ratio will change depending on the future growth rate expectations of investors.